Angiopoietin-2 and biliary diseases: Elevated serum, but not bile levels are associated with cholangiocarcinoma

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Voigtländer, Torsten ^a   David, Sascha ^a   Thamm, Kristina ^a   Schlué, Jerome ^a   Metzger, Jochen ^b   Manns, Michael P ^a   Lankisch, Tim O ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MOSAIQUES DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT STONE; BILE LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VASCULARIZATION; BILE; BLOOD; CHOLANGIOCARCINOMA; DIAGNOSTIC USE; EVALUATION STUDY; FLUORESCENCE; METABOLISM; NONPARAMETRIC TEST;

ANGIOPOIETIN-2; BILE; CHOLANGIOCARCINOMA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FLUORESCENCE; HUMANS; IMMUNOHISTOCHEMISTRY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84901260538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097046     Document Type: Article

References (29)

1. Tyson GL, El-Serag HB (2011) Risk factors for cholangiocarcinoma. Hepatology 54: 173-184. doi: 10.1002/hep.24351.
2. Khan SA, Toledano MB, Taylor-Robinson SD (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10: 77-82. doi: 10.1080/13651820801992641. (Pubitemid 351934989)
3. Razumilava N, Gores GJ (2013) Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 11: 13-21. doi: 10.1016/j.cgh.2012.09.009.
4. Karlsen TH, Boberg KM (2013) Update on primary sclerosing cholangitis. J Hepatol 59: 571-582. doi: 10.1016/j.jhep.2013.03.015.
5. Chapman MH, Webster GJM, Bannoo S, Johnson GJ, Wittmann J, et al. (2012) Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 24: 1051-1058. doi: 10.1097/MEG.0b013e3283554bbf.
6. Boberg KM, Lind GE (2011) Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 25: 753-764. doi: 10.1016/j.bpg.2011.10.002.
7. Alvaro D (2009) Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 25: 279-284. doi: 10.1097/MOG.0b013e328325a894.
8. Nehls O, Gregor M, Klump B (2004) Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24: 139-154. doi: 10.1055/s-2004-828891. (Pubitemid 38738343)
9. Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD (2011) Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 9: 434-9.e1. doi: 10.1016/j.cgh.2011.02.007.
10. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177. doi: 10.1038/nrm2639.
11. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180. doi: 10.1016/S0092-8674(00)81813-9. (Pubitemid 27010101)
12. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60. doi: 10.1126/science.277.5322.55. (Pubitemid 27450643)
13. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, et al. (2006) Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep15: 525-532. doi: 10.3892/or.15.3.525.
14. Negm AA, Schott A, Vonberg R-P, Weismueller TJ, Schneider AS, et al. (2010) Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc 72: 284-291. doi: 10.1016/j.gie.2010.02.043.
15. Malhi H, Gores GJ (2006) Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 23: 1287-1296. doi: 10.1111/j.1365-2036.2006.02900.x.
16. Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145: 1215-1229. doi: 10.1053/j.gastro.2013. 10.013.
17. Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, et al. (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53: 875-884. doi: 10.1002/hep.24103.
18. Metzger J, Negm AA, Plentz RR, Weismüller TJ, Wedemeyer J, et al. (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62: 122-130. doi: 10.1136/gutjnl-2012-302047.
19. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, et al. (2004) Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 101: 1609-1615. doi: 10.1002/cncr.20469. (Pubitemid 39318908)
20. Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, et al. (2007) Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med 147: 451-459. doi:10.7326/0003-4819-147-7-200710020-00003. (Pubitemid 351664517)
21. Everhart JE, Ruhl CE (2009) Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology 136: 1134-1144. doi: 10.1053/j.gastro.2009.02.038.
22. Leyva-Illades D, McMillin M, Quinn M, Demorrow S (2012) Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. Transl Gastrointest Cancer 1: 71-80. doi: 10.3978/j.issn.2224-4778. 2011.11.05.
23. McDougall SR, Anderson AR, Chaplain MA (2006) Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol 241: 564-589. doi: 10.1016/j.jtbi.2005.12.022. (Pubitemid 44041121)
24. Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, et al. (2007) Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 33: 1025-1029. doi: 10.1016/j.ejso.2007.02.020. (Pubitemid 47408741)
25. Xu LB, Liu C, Gao GQ, Yu XH, Zhang R, et al. (2010) Nerve growth factor-beta expression is associated with lymph node metastasis and nerve infiltration in human hilar cholangiocarcinoma. World J Surg 34: 1039-45. doi: 10.1007/s00268-010-0417-4.
26. Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2013) Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol 788: 341-348. doi: 10.1007/978-94-007-6627-3-46.
27. Li C, Sun CJ, Fan JC, Geng N, Li CH, et al. (2013) Angiopoietin-2 expression is correlated with angiogenesis and overall survival in oral squamous cell carcinoma. Med Oncol 30: 571. doi: 10.1007/s12032-013-0571-2.
28. Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, et al. (2007) Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 102: 2471-2481. doi:10.1111/j.1572-0241.2007.01377.x. (Pubitemid 47631757)
29. Diaz-Sanchez A, Matilla A, Nuñez O, Lorente R, Fernandez A, et al. (2013) Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scand J Gastroenterol 48: 334-343. doi: 10.3109/00365521.2012.746391.